FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:90-95 July 8, 1993 Number 2 Next

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background We have previously reported that inhaled heparin prevents allergic bronchoconstriction in sheep and inhibits the anti-IgE-mediated release of histamine from mast cells in vitro. Since the release of such mediators has been implicated in exercise-induced asthma, we investigated whether inhaled heparin could also attenuate the bronchoconstrictor response in this disease.

Methods On five days we studied 12 subjects with a history of exercise-induced asthma. On day 1 they underwent a standardized exercise challenge on a treadmill to document the presence of exercise-induced asthma. Minute ventilation was estimated with a calibrated respiratory inductive plethysmograph. The workload was increased until the heart rate reached 85 percent of the predicted maximal value, and was sustained for 10 minutes. The magnitude of bronchoconstriction was assessed by measuring specific airway conductance before and after the exercise. On day 2 the partial-thromboplastin time was measured in plasma obtained before and after the subjects inhaled a nebulized solution of heparin (1000 U per kilogram of body weight). On days 3 through 5 the subjects were pretreated with 4 ml of inhaled heparin (1000 U per kilogram), cromolyn sodium (20 mg), or placebo according to a single-blind, randomized, crossover design and underwent exercise challenge 45 minutes later. To exclude the possibility that heparin had any direct effect on airway smooth muscle, bronchial provocation with histamine was induced in five subjects on two further days after pretreatment with either heparin or placebo.

Results Inhaled heparin and cromolyn sodium had no effect on specific airway conductance at base line, but did attenuate the exercise-induced decreases in this variable: the mean (±SE) maximal decrease five minutes after exercise was 9 ±5 percent after pretreatment with heparin, as compared with 22 ±5 percent after pretreatment with cromolyn and 35 ±2 percent after pretreatment with placebo. Heparin did not change the partial-thromboplastin time and did not modify the bronchoconstrictor response to histamine.

Conclusions Inhaled heparin prevents exercise-induced asthma without influencing histamine-induced bronchoconstriction. This non-anticoagulant action of heparin is more likely to be related to a modulation of mediator release than to a direct effect on smooth muscle.

Source Information

From the Division of Pulmonary Disease, University of Miami School of Medicine, Miami, and Mount Sinai Medical Center, Miami Beach, Fla.

Address reprint requests to Dr. Ahmed at the Division of Pulmonary Disease, Mount Sinai Medical Center, 4300 Alton Rd., Miami Beach, FL 33140.

Full Text of this Article

This article has been cited by other articles:

• Maarsingh, H., Bossenga, B. E., Bos, I. S. T., Volders, H. H., Zaagsma, J., Meurs, H. (2009). L-Arginine deficiency causes airway hyperresponsiveness after the late asthmatic reaction. Eur Respir J 34: 191-199 [Abstract] [Full Text]  
• Shirk, M. B., Donahue, K. R., Shirvani, J. (2006). Unlabeled uses of nebulized medications.. Am J Health Syst Pharm 63: 1704-1716 [Abstract] [Full Text]  
• Serisier, D. J., Shute, J. K., Hockey, P. M., Higgins, B., Conway, J., Carroll, M. P. (2006). Inhaled heparin in cystic fibrosis. Eur Respir J 27: 354-358 [Abstract] [Full Text]  
• Parsons, J. P., Mastronarde, J. G. (2005). Exercise-Induced Bronchoconstriction in Athletes. Chest 128: 3966-3974 [Abstract] [Full Text]  
• Xu, J., Park, P. W., Kheradmand, F., Corry, D. B. (2005). Endogenous Attenuation of Allergic Lung Inflammation by Syndecan-1. J. Immunol. 174: 5758-5765 [Abstract] [Full Text]  
• Niven, A. S., Argyros, G. (2003). Alternate Treatments in Asthma. Chest 123: 1254-1265 [Full Text]  
• Caughey, G. H. (2003). Building A Better Heparin. Am. J. Respir. Cell Mol. Bio. 28: 129-132 [Full Text]  
• Paparella, D., Yau, T.M., Young, E. (2002). Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur. J. Cardiothorac. Surg. 21: 232-244 [Abstract] [Full Text]  
• SUZUKI, R., FREED, A. N. (2002). Heparin Inhibits Hyperventilation-Induced Late-Phase Hyperreactivity in Dogs. Am. J. Respir. Crit. Care Med. 165: 27-33 [Abstract] [Full Text]  
• SUZUKI, R., FREED, A. N. (2000). Heparin Inhibits Eicosanoid Metabolism and Hyperventilation-induced Bronchoconstriction in Dogs. Am. J. Respir. Crit. Care Med. 161: 1850-1854 [Abstract] [Full Text]  
• Ahmed, T., Ungo, J., Zhou, M., Campo, C. (2000). Inhibition of allergic late airway responses by inhaled heparin-derived oligosaccharides. J. Appl. Physiol. 88: 1721-1729 [Abstract] [Full Text]  
• BOUSQUET, J., JEFFERY, P. K., BUSSE, W. W., JOHNSON, M., VIGNOLA, A. M. (2000). Asthma . From Bronchoconstriction to Airways Inflammation and Remodeling. Am. J. Respir. Crit. Care Med. 161: 1720-1745 [Full Text]  
• Crapo, R. (2000). Guidelines for Methacholine and Exercise Challenge Testing---1999 . THIS OFFICIAL STATEMENT OF THE AMERICAN THORACIC SOCIETY WAS ADOPTED BY THE ATS BOARD OF DIRECTORS, JULY 1999. Am. J. Respir. Crit. Care Med. 161: 309-329 [Full Text]  
• BENDSTRUP, K. E., CHAMBERS, C. B., JENSEN, J. I., NEWHOUSE, M. T. (1999). Lung Deposition and Clearance of Inhaled 99mTc-Heparin in Healthy Volunteers. Am. J. Respir. Crit. Care Med. 160: 1653-1658 [Abstract] [Full Text]  
• AHMED, T., GONZALEZ, B. J., DANTA, I. (1999). Prevention of Exercise-induced Bronchoconstriction by Inhaled Low-molecular-weight Heparin. Am. J. Respir. Crit. Care Med. 160: 576-581 [Abstract] [Full Text]  
• Hauck, R. W., Schulz, C., Schomig, A., Hoffman, R. K., Panettieri, R. A. Jr. (1999). alpha -Thrombin stimulates contraction of human bronchial rings by activation of protease-activated receptors. Am. J. Physiol. Lung Cell. Mol. Physiol. 277: L22-L29 [Abstract] [Full Text]  
• Campo, C., Molinari, J. F., Ungo, J., Ahmed, T. (1999). Molecular-weight-dependent effects of nonanticoagulant heparins on allergic airway responses. J. Appl. Physiol. 86: 549-557 [Abstract] [Full Text]  
• ABUBAKAR, K., SCHMIDT, B., MONKMAN, S., WEBBER, C., deSA, D., ROBERTS, R. (1998). Heparin Improves Gas Exchange during Experimental Acute Lung Injury in Newborn Piglets. Am. J. Respir. Crit. Care Med. 158: 1620-1625 [Abstract] [Full Text]  
• MOLINARI, J. F., CAMPO, C., SHAKIR, S., AHMED, T. (1998). Inhibition of Antigen-induced Airway Hyperresponsiveness by Ultralow Molecular-weight Heparin. Am. J. Respir. Crit. Care Med. 157: 887-893 [Abstract] [Full Text]  
• Martinez-Salas, J., Mendelssohn, R., Abraham, W. M., Hsiao, B., Ahmed, T. (1998). Inhibition of allergic airway responses by inhaled low-molecular-weight heparins: molecular-weight dependence. J. Appl. Physiol. 84: 222-228 [Abstract] [Full Text]  
• Fryer, A., Huang, Y.-C., Rao, G., Jacoby, D., Mancilla, E., Whorton, R., Piantadosi, C. A., Kennedy, T., Hoidal, J. (1997). Selective O-Desulfation Produces Nonanticoagulant Heparin that Retains Pharmacological Activity in the Lung,. J. Pharmacol. Exp. Ther. 282: 208-219 [Abstract] [Full Text]  
• ELROD, K. C., MOORE, W. R., ABRAHAM, W. M., TANAKA, R. D. (1997). Lactoferrin, a Potent Tryptase Inhibitor, Abolishes Late-Phase Airway Responses in Allergic Sheep. Am. J. Respir. Crit. Care Med. 156: 375-381 [Abstract] [Full Text]  
• Draper, D. (1995). Inference and Hierarchical Modeling in the Social Sciences. JOURNAL OF EDUCATIONAL AND BEHAVIORAL STATISTICS 20: 115-147 [Abstract]  
• Lane, D. A., Adams, L. (1993). Non-Anticoagulant Uses of Heparin. NEJM 329: 129-130 [Full Text]